Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00401193
Other study ID # XP12B-MR-301
Secondary ID
Status Completed
Phase Phase 3
First received November 9, 2006
Last updated April 23, 2015
Start date November 2006
Est. completion date May 2008

Study information

Verified date April 2015
Source Ferring Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.


Recruitment information / eligibility

Status Completed
Enrollment 304
Est. completion date May 2008
Est. primary completion date May 2008
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria:

- Women with menorrhagia

- 18-49 years of age

- Regularly occurring menstrual periods

Exclusion Criteria:

- History or presence of clinically significant disease or abnormalities that may confound the study

- History of bilateral oophorectomy or hysterectomy

- Hormone therapy for birth control

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Tranexamic acid tablets
3900 mg/Day
Tranexamic acid tablets
1950 mg/Day
Placebo tablets


Locations

Country Name City State
United States Investigative Site Albuquerque New Mexico
United States Investigative Site Ann Arbor Michigan
United States Investigative Site Atlanta Georgia
United States Investigative Site Austin Texas
United States Investigative Site Baltimore Maryland
United States Investigative Site Bingham Farms Michigan
United States Investigative Site Birmingham Alabama
United States Investigative Site Bismarck North Dakota
United States Investigative Site Bloomington Indiana
United States Investigative Site Boise Idaho
United States Investigative Site Bristol Tennessee
United States Investigative Site Bryan Texas
United States Investigative Site Burlington Vermont
United States Investigative Site Clarksville Tennessee
United States Investigative Site Cleveland Ohio
United States Investigative Site Cleveland Ohio
United States Investigative Site Decatur Georgia
United States Investigative Site Denver Colorado
United States Investigative Site Durham North Carolina
United States Investigative Site Eugene Oregon
United States Investigative Site Fort Worth Texas
United States Investigative Site Gainesville Florida
United States Investigative Site Gallipolis Ohio
United States Investigative Site Grand Rapids Michigan
United States Investigative Site Greenville South Carolina
United States Investigative Site Groton Connecticut
United States Investigative Site Houston Texas
United States Investigative Site Idaho Falls Idaho
United States Investigative Site Jacksonville Florida
United States Investigative Site Kansas City Missouri
United States Investigative Site Las Vegas Nevada
United States Investigative Site Lawrenceville New Jersey
United States Investigative Site Levittown Pennsylvania
United States Investigative Site Lighthouse Point Florida
United States Investigative Site Little Rock Arkansas
United States Investigative Site Los Alamitos California
United States Investigative Site Los Angeles California
United States Investigative Site Marrero Louisiana
United States Investigative Site McCook Nebraska
United States Investigative Site Miami Florida
United States Investigative Site Miami Beach Florida
United States Investigative Site Missoula Montana
United States Investigative Site Moorestown New Jersey
United States Investigative Site Nashville Tennessee
United States Investigative Site New Brunswick New Jersey
United States Investigative Site New Port Richey Florida
United States Investigative Site New York New York
United States Investigative Site Newton Kansas
United States Investigative Site Norfolk Virginia
United States Investigative Site Oklahoma City Oklahoma
United States Investigative Site Oklahoma City Oklahoma
United States Investigative Site Overland Park Kansas
United States Investigative Site Paw Paw Michigan
United States Investigative Site Philadelphia Pennsylvania
United States Investigative Site Philadelphia Pennsylvania
United States Investigative Site Phoenix Arizona
United States Investigative Site Phoenixville Pennsylvania
United States Investigative Site Plano Texas
United States Investigative Site Pleasant Grove Utah
United States Investigative Site Portland Oregon
United States Investigative Site Raleigh North Carolina
United States Investigative Site Renton Washington
United States Investigative Site Richmond Virginia
United States Investigative Site Rochester New York
United States Investigative Site Salt Lake City Utah
United States Investigative Site San Diego California
United States Investigative Site Sarasota Florida
United States Investigative Site Searcy Arkansas
United States Investigative Site Sioux Falls South Dakota
United States Investigative Site St. Clair Shores Michigan
United States Investigative Site Strafford Pennsylvania
United States Investigative Site Temple Texas
United States Investigative Site Tucson Arizona
United States Investigative Site Tucson Arizona
United States Investigative Site Waco Texas
United States Investigative Site Webster Texas
United States Investigative Site West Jordan Utah
United States Investigative Site West Valley City Utah
United States Investigative Site Wexford Pennsylvania
United States Investigative Site Winston-Salem North Carolina
United States Investigative Site Woodlands Texas
United States Investigative Site Wynnewood Pennsylvania
United States Investigative Site Zanesville Ohio

Sponsors (1)

Lead Sponsor Collaborator
Ferring Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Reduction From Baseline in Menstrual Blood Loss (MBL) reduction of menstrual blood loss in mL Baseline MBL over 3 menstrual cycles No
Secondary Patient Reported Outcome Measure of Limitations in Social or Leisure Activities Associated With Heavy Menstrual Bleeding A positive unit change of the mean relects an improvement from baseline. Patient reported outcome scores had the following response categories: 1=not limited at all; 2=slightly limited; 3=moderately limited; 4=quite a bit limited; and 5=extremely limited Baseline scores over 3 menstrual cycles No
Secondary Patient Reported Outome Measure of Limitations in Physical Activities Associated With Heavy Menstrual Bleeding A positive unit change of the mean relects an improvement from baseline. Patient reported outcome scores had the following response categories: 1=not limited at all; 2=slightly limited; 3=moderately limited; 4=quite a bit limited; and 5=extremely limited Baseline scores over 3 menstrual cycles No
Secondary Responder Analysis - Reduction in Large Stains Percentage of subjects who experienced a reduction from baseline in the frequency of large stains Baseline over 3 mentrual cycles No
See also
  Status Clinical Trial Phase
Completed NCT02824224 - Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS) Phase 4
Withdrawn NCT01651468 - The Effect of the Nutraceutical "Hemofix" on the Coagulation System N/A
Recruiting NCT02616731 - Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD Phase 1/Phase 2
Terminated NCT02087228 - Evaluation of the Endometrial Cavity After Endometrial Ablation N/A
Withdrawn NCT00953641 - Vaginal Misoprostol for Cervical Ripening Prior to Endometrial Biopsy Phase 3
Completed NCT01436903 - Chances for Success of CavatermTM Surgery as a Function of Uterus Probe Length Phase 4
Withdrawn NCT00768742 - Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study N/A
Completed NCT00152256 - A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids Phase 3
Completed NCT00156195 - Study to Evaluate the Safety of Asoprisnil in the Treatment of Uterine Fibroids Phase 3
Completed NCT00160381 - A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids Phase 3
Completed NCT02228174 - Sonography Guided Transcervical Ablation of Uterine Fibroids N/A
Terminated NCT01969396 - Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology N/A
Completed NCT00393198 - Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia Phase 4
Completed NCT00386308 - Efficacy and Safety Study of XP12B in Women With Menorrhagia Phase 3
Completed NCT00966264 - Hysterectomy and Levonorgestrel Releasing Intrauterine System (LNG-IUS) in the Treatment of Menorrhagia Phase 3
Completed NCT00904709 - The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders Phase 4
Recruiting NCT03670680 - Efficiency of Lina LibrataTM System N/A
Completed NCT02584088 - Ultrasound Appearance of the Endometrium Post Radio-Frequency Ablation
Completed NCT02835391 - PerClot Compared to Usual Care in Gynaecology Procedures N/A
Completed NCT02304510 - Prevalence of Heavy Menstrual Bleeding in Female Population Living in Beijing